News
LUMO
7.71
+0.92%
0.07
Lumos Pharma to Participate in Upcoming Investor Conferences
AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the following upcoming investors conferen...
GlobeNewswire · 05/16 20:05
Lumos Pharma: Q1 Earnings Insights
Lumos Pharma (NASDAQ:LUMO) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Lumos Pharma missed estimated earnings by 3.37%, reporting an EPS of $-0.92 versus an esti...
Benzinga · 05/10 22:23
Lumos Pharma Q1 EPS $(0.92) Misses $(0.89) Estimate
Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.89) by 3.37 percent. This is a 11.54 percent increase over losses of $(1.04) per share from the
Benzinga · 05/10 20:32
-- Earnings Flash (LUMO) LUMOS PHARMA Reports Q1 Revenue $111,000
MT Newswires · 05/10 16:06
Earnings Scheduled For May 10, 2022
  Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
Benzinga · 05/10 09:18
Lumos Pharma's Earnings: A Preview
Lumos Pharma (NASDAQ:LUMO) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Lumos Pharma will report an earnings per share (EPS) of $-0.89.
Benzinga · 05/09 17:36
Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 05/06 14:25
Lumos Pharma Announces A Clinical Collaboration With Massachusetts General Hospital To Evaluate Oral LUM-201 In Nonalcoholic Fatty Liver Disease In A Phase 2 Investigator-initiated Trial
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial AUSTIN, Texas, May
Benzinga · 05/05 13:10
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial
The IND application for this pilot trial to evaluate oral growth hormone secretagogue, LUM-201, in NAFLD has been approved by the FDAAUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical compan...
GlobeNewswire · 05/05 13:00
Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022
AUSTIN, Tex., April 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its first quarter 2022 financial results after market close on Tuesday, May 10, 2022. The company ...
GlobeNewswire · 04/26 13:00
BRIEF-Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 Trial Evaluating Oral LUM-201 in PGHD
reuters.com · 04/11 14:54
Lumos Pharma Says 50% of Patients Randomized in Trial of Growth Hormone Deficiency Treatment
MT Newswires · 04/11 10:53
Lumos Pharma to Participate in the Cantor Rare Disease Symposium
AUSTIN, Texas, March 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that John McKew, PhD, President and Chief Scientific Officer of Lumos Pharma...
GlobeNewswire · 03/23 20:05
Recap: Lumos Pharma Q4 Earnings
Lumos Pharma (NASDAQ:LUMO) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Benzinga · 03/10 21:53
Lumos Pharma GAAP EPS of -$3.65 beats by $0.24, revenue of $0.23M beats by $0.22M
Lumos Pharma press release (NASDAQ:LUMO): FY GAAP EPS of -$3.65 beats by $0.24. Revenue of $0.23M (+35.3% Y/Y) beats by $0.22M.
Seekingalpha · 03/10 21:02
Lumos Pharma FY 2021 Earnings Preview
Lumos Pharma (NASDAQ:LUMO) is scheduled to announce FY earnings results on Thursday, March 10th, after market close. The consensus EPS Estimate is -$3.89 (-318.3% Y/Y) and the consensus Revenue Estimate
Seekingalpha · 03/09 22:35
Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022
AUSTIN, Texas, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its full year 2021 financial results after market close ...
GlobeNewswire · 02/23 14:00
Great news for Lumos Pharma, Inc. (NASDAQ:LUMO): Insiders acquired stock in large numbers last year
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
Simply Wall St. · 02/14 17:05
MAPS, IBKR and MNDY among after hour movers
Gainers: WM Technology (NASDAQ:MAPS) +8%. Interactive Brokers Group (NASDAQ:IBKR) +7%. Texas Instruments Incorporated (NASDAQ:TXN) +3%. Dogness (International) Corporation (NASDAQ:DOGZ) +3%. Niu Technologies (NASDAQ:NIU) +2%. Losers: Navient Corporation (N...
Seekingalpha · 01/25 22:59
More
Webull provides a variety of real-time LUMO stock news. You can receive the latest news about Lumos Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About LUMO
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, acquiring, developing and commercialization of products, and therapies for people with rare diseases. The Company's lead product candidate is LUM-201, a therapy for pediatric growth hormone deficiency (PGHD) and other rare endocrine disorders. LUM-201 stimulates growth hormone (GH) through the GH secretagogue receptor. Its product provides a differentiated mechanism of action to treat rare endocrine disorders by increasing the amplitude of endogenous and pulsatile GH secretion. LUM-201 is an orally administered small molecule, which is a GH secretagogue for rare endocrine disorders where injectable recombinant human growth hormone (rhGH) is approved. The Company’s pipeline features development programs in rare diseases associated with growth hormone deficiencies.